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Abstract Dendritic cells (DCs) are central players of the
immune response. To date, DC-based immunotherapy is
explored worldwide in clinical vaccination trials with can-
cer patients, predominantly with ex vivo-cultured mono-
cyte-derived DCs (moDCs). However, the extensive culture
period and compounds required to diVerentiate them into
DCs may negatively aVect their immunological potential.
Therefore, it is attractive to consider alternative DC
sources, such as blood DCs. Two major types of naturally
occurring DCs circulate in peripheral blood, myeloid DCs
(mDCs) and plasmacytoid (pDCs). These DC subsets
express diVerent surface molecules and are suggested to
have distinct functions. Besides scavenging pathogens and
presenting antigens, DCs secrete cytokines, all of which is
vital for both the acquired and the innate immune system.
These immunological functions relate to Toll-like receptors
(TLRs) expressed by DCs. TLRs recognize pathogen-
derived products and subsequently provoke DC maturation,
antigen presentation and cytokine secretion. However, not
every TLR is expressed on each DC subset nor causes the
same eVects when activated. Considering the large amount
of clinical trials using DC-based immunotherapy for cancer
patients and the decisive role of TLRs in DC maturation,
this review summarizes TLR expression in diVerent DC
subsets in relation to their function. Emphasis will be given
to the therapeutic potential of TLR-matured DC subsets for
DC-based immunotherapy.
Keywords Dendritic cell vaccination · Myeloid dendritic 
cells · Plasmacytoid dendritic cells · Toll-like receptors
Introduction
To date, dendritic cell (DC)-based immunotherapy is
explored worldwide in clinical vaccination trials, predomi-
nantly in cancer patients (reviewed in [1]). The therapy
consists of autologous ex vivo-cultured, antigen-loaded
monocyte-derived DCs (moDCs) or CD34+ progenitor-
derived DCs that are administered to patients with the inten-
tion of inducing antigen-speciWc T and B cell responses. The
generation of anti-tumor immune responses involves the
induction of Th1-type CD4+ T cells and CD8+ cytotoxic T
lymphocytes. Although DC-based immunotherapy potently
induces immunological responses, thus far only a limited
number of clinical responses have been observed [2]. It is
unclear whether DCs diVerentiated ex vivo from precursor
cells are the most optimal source of DCs for the induction of
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potent immune responses. The extensive culture period (8–
9 days) and compounds required to diVerentiate them into
DCs may negatively aVect DC function, especially migration
[3, 4]. Therefore, it is attractive to consider alternative DC
sources, such as blood DCs. Two major types of DCs circu-
late in the blood, which can be distinguished by the presence
of diVerent surface markers: myeloid dendritic cells (mDCs)
and plasmacytoid dendritic cells (pDCs).
In melanoma patients, we demonstrated that moDC matu-
ration is a prerequisite for the generation of tumor-speciWc T
cell responses [5]. While blood DCs may not require exten-
sive culture, for these cells activation is essential prior to
reinfusion, as immature DCs may cause tolerance rather than
immunity. To date, most clinical studies use TNF, IL-1,
IL-6 and prostaglandin E2 for moDCs maturation. However,
it has been suggested that the current protocols used to gener-
ate mature moDCs may not result in optimal Th1 responses.
Murine studies have shown that activation of DCs by solely
pro-inXammatory cytokines yields DCs that support CD4+ T
cell clonal expansion, but fail to eYciently direct helper T
cell diVerentiation. In contrast, exposure of DCs to pathogen
associated molecular patterns (PAMPs) induces DCs that
produce high levels of the Th1 skewing cytokine IL-12p70
and promote eYcient T cell help. PAMPs are recognized by
pattern recognition receptors (PRRs). MoDCs, mDCs and
pDCs express diVerent repertoires of PRRs and respond dis-
similarly to extracellular stimuli, suggesting that the DC sub-
sets have specialized and complementary functions [6]. In
this review we summarize the expression of the most well-
known PRRs, Toll-like receptors (TLRs), on diVerent DC
subtypes in relation to their function.
Dendritic cell subsets
Dendritic cells are the most potent professional antigen-
presenting cells (APC) of the immune system. Upon infec-
tion or inXammation, immature DCs are activated and
diVerentiate into mature DCs that instruct and activate B
and T lymphocytes, the mediators of adaptive immunity
[7]. DCs take up and process pathogens and present patho-
gen-derived peptides to T cells via major histocompatibility
complex (MHC) molecules. The recognition of the pep-
tide–MHC complex (signal 1) and stimulation via costimu-
latory molecules (signal 2) and cytokines (signal 3) lead to
the activation of T cells. The immunological outcome
strongly depends on the activation state of DCs. Resting
DCs or DCs receiving inhibitory signals, such as IL-10 or
corticosteroids, induce immune tolerance via T cell deletion
or induction of regulatory T cells, whereas mature DCs
induce immunity.
The classical view of DCs is that of immature DCs, wait-
ing for pathogens to be recognized, residing mainly in parts
of the body that are in close contact with the outside world,
such as skin and mucosal tissue. These immature DCs are
able to quickly sense and take up pathogens that could harm
the host. After recognition of a pathogen, the DCs mature
and migrate to lymphoid tissues to present the pathogenic
peptides to T cells [7]. DC maturation comprises a tightly
controlled series of events, including downmodulation of
endocytic and phagocytic receptors, upregulation of
costimulatory molecules, such as CD40, CD58, CD80 and
CD86, changes in morphology and reorganization of the
DC lysosomal and MHC class II compartment. DC matura-
tion is highly complex and should be regarded as a Xexible
process, the outcome of which depends on the type of sig-
nals a DC receives in the periphery.
The DC population is a heterogeneous population. The
DC subtypes diVer in function, localization and phenotype.
In human peripheral blood, two main populations of DCs can
be distinguished: CD11c expressing myeloid DCs (mDCs)
and CD11c negative plasmacytoid DCs (pDCs) [8]. These
DCs express distinct PRRs and respond to diVerent patho-
genic stimuli, suggesting that each subset has a specialized
function in directing immune responses. However, both
mDCs and pDCs have the capacity to initiate suitable T cell
responses, depending on the pathogens they encounter.
Plasmacytoid dendritic cells
Human pDCs are a rare subpopulation of cells; they consti-
tute only 0.1% of all blood mononuclear cells. PDCs are
devoid of lineage markers and myeloid antigens and do not
express CD11c. PDCs express BDCA2 and BDCA4 [9]. In
the steady state, they are round, non-dendritic and relatively
long-lived cells. After receiving inXammatory stimuli,
pDCs develop dendritic cell morphology and function.
Most notably, pDCs produce large amounts of type I inter-
ferons in response to viruses and are therefore crucial to
antiviral immunity [10].
Initially, pDCs were thought to be of lymphoid origin
[11]. However, several human and mouse studies pointed
out that the cytokine Flt3L is of importance for pDC devel-
opment and that pDCs can develop out of myeloid precur-
sors under the inXuence of Flt3L [10, 12, 13]. PDCs reside
in blood as well as in several lymphoid organs, and some
recent studies suggest functional diVerentiation between
diVerent tissue-residing pDCs [14]. Whether these are
actual pDC subsets or whether environmental factors inXu-
ence pDC function is not clear yet.
Myeloid dendritic cells
Myeloid DCs found in peripheral blood are deWned by the
expression of myeloid markers, such as CD13 and CD33.
They lack lineage-speciWc markers (CD3, CD14, CD19 and
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CD56), but express MHC class II and CD11c. The mDC
population can be further subdivided based on diVerential
surface expression of CD1c (BDCA1), CD16 and BDCA3.
In addition, another small subset of CD16-expressing DC,
termed M-DC8 DCs or SlanDCs, has been described [15].
CD16-mDCs comprise the largest population of mDCs (65–
75% of total mDC population), followed by CD1c-mDCs
(10–20%) and BDCA3-mDCs (3–5%) [16, 17]. Although
CD16-mDCs have the highest frequency in human periphe-
ral blood, CD1c-mDCs have been studied most extensively.
The mDC subsets diVer in their expression of cell surface
markers and potency to stimulate T cells [16–18]. For
instance, the recently identiWed C-type lectin receptor
CLEC9a is expressed only by BDCA3-mDCs [19]. Accord-
ing to MacDonald et al. [16] CD1c-mDCs are the most
potent T cell stimulators of the three mDC subpopulations.
Monocyte-derived dendritic cells
Since the frequency of circulating mDCs in human blood is
very low, many studies exploit in vitro-generated “monocyte-
derived dendritic cells” (moDCs) [20]. Monocytes are pre-
DCs that originate from myeloid progenitor cells. In vivo,
monocytes are capable of transforming into DCs after sensing
inXammatory signals and are important for the replenishment
of dendritic cells in the host. In vitro, a cocktail of granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) and
interleukin-4 (IL-4) diVerentiates monocytes into moDCs
[20]. MoDCs are the major DC type used in clinical DC vac-
cination studies [2, 21]. Whether these moDCs reXect imma-
ture “steady state” in vivo mDCs remains to be seen, as most
of these moDCs show a dramatically higher expression of
MHC molecules and costimulatory molecules compared to
freshly isolated immature mDCs [22]. In addition, moDCs
and mDCs respond diVerently to physiologic stimuli and
diVer in their ability to stimulate T cells [23, 24]. Therefore,
although in vitro-generated moDCs share many phenotypic
and functional characteristics with circulating mDCs, it is yet
unclear to what extend they resemble blood DCs.
In addition to monocytes, CD34+ precursors in blood are
also used to generate DCs for vaccination of cancer patients.
They consist of two populations: one with Langerhans cell-
like properties and one called interstitial/dermal DCs with
properties resembling moDCs. Immunological and clinical
responses have been observed in cancer patients vaccinated
with CD34+-derived DCs [25]. However, to date most clini-
cal studies use monocytes to generate DCs.
Pathogen recognition by Toll-like receptors
In evolution, the immune system has acquired various
receptor families that recognize several crucial molecular
components of pathogens. This set of PAMPs recognized
by the immune system is limited and constituted mostly of
general molecular patterns that are absent on cells of the
host and are essential for survival of the microbe. On DC
membranes, two main PRR families are present: C-type
lectins and Toll-like receptors (TLRs), of which the TLR
family is best characterized and recognizes the most diverse
group of PAMPs. Nowadays, 15 mammalian Toll-like
receptors are found (TLR1-15), of which 10 are in humans
[26, 27]. The binding partners of the recently discovered
TLR10, TLR12, TLR13 and TLR15 are unknown. TLR11
is only expressed in mice and recent studies suggest that
TLR11 associates with molecules originating from uropath-
ogenic bacteria and Toxoplasma Gondii [28, 29]. The bet-
ter-described TLR1-9 can be divided into two main groups:
extracellular TLRs that are found on the cell surface
(TLR1, TLR2, TLR4, TLR5 and TLR6) and the intracellu-
lar TLRs that are located in the endosomal compartments
(TLR3, TLR7, TLR8 and TLR9). In general, intracellular
TLRs recognize nucleotide-containing structures, for exam-
ple RNA molecules (TLR3, TLR7 and TLR8) and unme-
thylated CpG DNA (TLR9), originating from viruses and
bacteria. Extracellular TLRs recognize exterior components
of bacteria and fungi, e.g., cell wall components. Examples
of ligands include lipopolysaccharide (LPS) for TLR4,
Xagellin for TLR5 and peptidoglycan for TLR2. TLR2
forms heterodimers with either TLR1 or TLR6. The TLR1/
2 heterodimer recognizes bacterial triacyl lipopeptides and
TLR2/6 recognizes bacterial diacyl lipopeptides. Besides
PAMPs derived from pathogens, TLRs have been proposed
to recognize endogenous ligands such as heat-shock pro-
teins or necrotic cells [30, 31]. The signaling pathways
associated with ligation of the diVerent TLRs are not identi-
cal and therefore distinct biological responses are initiated.
Ligand binding of TLRs recruits one or more adaptor mole-
cules. The diVerence in signaling outcome (e.g., variation
in cytokine production) can be explained in part by the use
of diVerent adaptor molecules by the Toll-like receptors.
All TLRs, except TLR3, rely on MyD88 for signal trans-
duction. TLR3 uses TRIF as adaptor molecule, whereas
TLR4 is able to recruit both MyD88 and TRIF [32].
TLR expression and functionality in DC subpopulations
DCs show diVerent expression levels of TLRs and respond
dissimilarly to TLR ligands. The expression of TLRs varies
with species, DC subtype and maturation stage. In this review,
we focus on TLR expression and function in human DC sub-
sets. We have divided the human DC population into three
groups: in vitro-generated moDCs and circulating mDCs and
pDCs. Expression of TLRs and the eVects of TLR activation
in the three DC subtypes are summarized in Table 1.
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Table 1 TLR expression and functionality on DC subtypes
DC subtype TLR Expression EVects of activation References
moDC 1 + See TLR2 [35, 39–41, 44, 71]
2 ++ Increased IL-6, IL-8, IL-10, IL-12, TNF [35, 38–41, 44, 71]
Low IFN response and no IFN response
3 + SpeciWc IFN mRNA upregulation (not IFN) [35, 38–41, 44, 71]
4 ++ Upregulation of CD80, CD86, CD83, CCR7 [35, 38–41, 44, 71]
Secretion of IFN, IFN, IL-1, IL-12p70, IL-13, IP-10
Decreased endocytic capacity
5 + Upregulation of CD80, CD86, CD83, CCR7 [35, 39–41, 44, 71]
Secretion of IFN, IL-1, TNF, IL-8, IL-12p40 (not IL-12p70), IL-13
Decreased endocytic capacity
6 § See TLR2 [35, 38, 39, 41, 71]
7 § – [35, 39, 41, 71]
8 + Increased TNF, IL-8, IL-12p40, MCP-1, CCL2, CCL3, CCL4, CCL5 [35, 39, 41, 71]
9 ¡ [35, 39, 41, 71]
10 ¡ [39, 41]
mDC 1 + See TLR2 [35–37, 39, 51]
2 ++ Upregulation of CCR7, IL-6, IL-10, IL-12p70,TNF, no INF [35–39, 51]
3 ++ IFN (intermediate), IL-12p70 (high) [35–39, 51]
No TNF or IL-6
4 + Upregulation of CD80, CD86, CD83, CD40, CCR7 [34–39, 51]
Secretion or upregulation of CCR7, IL-6, IL-8, IL-10, IL-12p70
No IFN response
5 + Upregulation of CD80, CD86, CD83, CCR7 [35–37, 39]
Secretion of TNF and IL-8
Upregulation of CCR7
6 + See TLR2 [35–37, 39, 51]
7 + Upregulation of CD40, CD80 and CD86 [34–37, 39, 51]
Secretion of IL-12p70
No IFN response
8 § See TLR7 [35–37, 39, 51]
9 ¡ [34–37, 39, 51]
10 + No ligand known [36, 39, 51]
pDC 1 § [35–37, 50, 51]
2 ¡ [35–38, 50, 51]
3 ¡ [35–38, 50, 51]
4 ¡ [34–38, 50, 51]
5 ¡ [35–37, 50]
6 ¡ [35–37, 50, 51]
7 ++ Upregulation of CD40, CD80, CD86, CCR7 [34–37, 50, 51]
Very high IFN response
No IL-12p70 response
8 ¡ [35–37, 50, 51]
9 +++ Upregulation of CD40, CD80, CD86, CD83, HLA-DR, CCR7 [34–37, 50, 51]
Upregulation of IFN (very high), IFN (lower), 
IL-6, TNF (low), IL-8, IP-10
No IL-10 secretion
10 + No ligand known [36, 50–52]
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TLR expression and activation: moDCs and mDCs 
compared
DCs derived in vitro from monocytes (moDCs) have pro-
vided immunologists important insights into the biology of
DCs. Because of the large amounts of clinical trials using
moDCs as an alternative for naturally occurring blood
mDCs, we here compare the TLR expression proWle in
human moDCs and their blood-isolated mDC counterparts.
Of the three blood mDC subpopulations, CD1c-mDCs have
been studied most extensively. Only a study by Piccioli
et al. compared the expression and function of TLRs in
the three circulating mDC subtypes, CD16-mDCs, CD1c-
mDCs and BDCA3-mDCs. They detected the expression of
TLR1-10 at the RNA level in all three mDC subsets, with
the exception of TLR3, which was not expressed by CD16-
mDCs. In addition, both CD16-mDCs and CD1c-mDCs
strongly responded to all TLR agonists, except the TLR9
agonist CpG. Interestingly, CD16-mDCs were responsive
to the TLR3 ligand poly(I:C), while TLR3-mRNA was not
detected in these cells. The authors suggest that poly(I:C)
may activate CD16-mDCs through TLR3-independent
mechanisms [17], such as cytosolic RNA sensors like RIG-
like helicases [33]. Another possibility may be that minor
contaminations of, for instance, endotoxin in poly(I:C)
have activated other TLRs. Due to the low frequency of
BDCA3-mDC in peripheral blood, no functional studies
were performed on this mDC subset.
Since other studies on TLR expression and function in
mDC subtypes are lacking, we focused on CD1c-mDCs
when comparing moDCs with blood mDCs. Human moDCs
and CD1c-mDCs show very similar TLR expression proWles
(Table 1). Both DC subsets express the extracellular TLRs
(TLR1, TLR2, TLR4, TLR5 and TLR6) and the endosomal
TLRs (TLR3 and TLR8) (Table 1). In addition, both moDCs
and CD1c-mDCs respond to speciWc ligands of these TLRs,
leading to a mature phenotype and production of proinXam-
matory cytokines [34–42]. However, some signiWcant diVer-
ences between moDCs and CD1c-mDCs in TLR expression
and ligand reactivity were found.
Most notably, moDCs showed negligible TLR10 expres-
sion, whereas blood mDCs did express TLR10. An exten-
sive qPCR expression proWling by Means et al. [39]
revealed that mDCs have 20-fold higher expression levels
of TLR10 mRNA compared to moDCs. MRNA expression
of TLR10 in mDCs was even comparable to that of TLR5.
Unfortunately, the ligands and functionality of TLR10 are
still unknown, so this diVerence between moDCs and
mDCs could not be explained. However, since TLR10 is
also expressed by regulatory T cells [43], TLR10 activation
on DCs may induce tolerogenic DCs. The fact that moDCs
have a more mature phenotype [22] may thus explain the
absence of TLR10 in moDCs.
Iwasaki and Medzhitov [27] concluded that human
mDCs totally lacked TLR4 expression. The authors mainly
base their conclusion on a study performed by Visintin
et al. [44]. However, their results were contradicted by Ito
et al. [34] and Matsumoto et al. [38] in 2002 and 2003,
respectively, who showed that freshly isolated human blood
mDCs expressed TLR4. This was conWrmed by experi-
ments in the same study of Ito et al. [34] which showed that
stimulation of mDCs with LPS induced the production of
IL12. According to Means et al. [39] moDCs secrete type I
IFNs on LPS administration, whereas this ligand did not
provoke type I IFN secretion in mDCs. While this was con-
Wrmed by Matsumoto et al. [38], the function of type I IFN
secretion after LPS challenge remains unclear, as type I
IFNs have anti-viral rather than anti-bacterial properties.
The disparity in IFN secretion may also be caused by the
diVerence in maturation stage between moDCs and CD1c-
mDCs. Muzio et al. [40] showed that as diVerentiation of
monocytes progresses toward moDCs, the expression
of TLR 3, 4 and 5 increases. Eventually the expression of
TLR4 in moDCs is higher than that in CD1c-mDCs. This
higher number of TLR4 molecules per cell may explain the
diVerence in type I IFN secretion between moDCs and
CD1c-mDCs. A high number of TLR4 molecules might
induce a broader immune response: a low number of TLR4
molecules is able to only activate the MyD88 pathway,
resulting in an immune response without an IFN response,
whereas a higher amount of TLR4 molecules might be able
to activate both the MyD88 and TRIF pathway, leading to a
broader immune response, including production of type
IFNs [45]. This is in line with the Wnding that the TRIF
adapter protein in non-plasmacytoid DCs is mainly respon-
sible for the activation of transcription factors that induce
type I interferons [45].
TLR1, 2 and 6 are expressed by both moDCs and mDCs
(Table 1) [35–39, 41]. Through the formation of heterodi-
mers with TLR1 or TLR6, TLR2 gains the capacity to bind
a wide variety of bacterial and yeast-derived ligands. Con-
sequently, this plays a central function in pathogen recogni-
tion by DCs. TLR1/2/6 activation leads to DC maturation
and secretion of several cytokines important in immune
system activation, especially IL-6, IL-8, IL-10, IL-12 and
TNF-. DiVerences in expression between moDCs and
mDCs in TLR1, TLR2 and TLR6 expression and reactivity
are negligible.
TLR5 expression was evident in both moDCs and
CD1c-mDCs as indicated in Table 1. Means et al. [39]
especially investigated the role of TLR5 and its main
ligand, bacterial Xagellin, in moDCs and to a lesser extent
in mDCs. They found increased surface expression of mat-
uration markers for both, without the induction of a type I
IFN response, which is expected considering the bacterial
origin of Xagellin.
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Studies on TLR7 expression on moDCs or mDCs show
conXicting results. This inconsistency was also noted in the
review by Iwasaki and Medzhitov [27]. It was especially
fueled by the contradictory results of Jarossay et al. and
Krug et al. [35]. Using three diVerent primer sets for RT-
PCR on TLR7, Ito et al. [34] concluded that human mDCs
do express TLR7. For TLR7 expression in moDCs, there is
still disagreement between studies; however, the most
recent Wndings suggest that moDCs indeed express TLR7
[39]. For moDCs, a thorough study of TLR7 mRNA/pro-
tein expression, as was performed for mDCs by Ito et al., is
lacking. ConWrmation of TLR7 protein expression is diY-
cult due to low expression and a lack of good antibodies.
Therefore, TLR7 expression in moDCs is still unclear, as
indicated by the “+/¡” in Table 1. TLR8, the “near cousin”
of TLR7, was found to be consistently expressed in lower
amounts in both moDCs and mDCs. As TLR7 and TLR8
share the same ligands, it was impossible to attribute TLR8
as the binding receptor responsible for the secretion of
cytokines or DC maturation after, for example, R848 chal-
lenge [34].
Human moDCs and mDCs do not express TLR9 and do
not respond to TLR9 ligands [34, 37]. TLR9 is only
expressed by pDCs in the human setting and is responsible
for a very high type I IFN response [46].
In summary, data suggest that both moDCs and mDCs
express TLR1-8 and not TLR9, and only mDCs express
TLR10. The mRNA expression of these receptors was con-
Wrmed by DC reactivity studies using TLR ligands, as sum-
marized in Table 1.
TLR expression by human pDCs
Evidence suggests that pDCs are specialized in the recogni-
tion of viral antigens, as they largely lack expression of
extracellular TLRs and only express TLRs that recognize
and respond to viral antigens. PDCs abundantly express
TLR7 and TLR9 in their endosomal compartments. In addi-
tion, triggering of TLR7 and TLR9 on pDCs leads to high
type I IFN secretion and a typical mature DC phenotype,
i.e., upregulation of expression of major histocompatibility
molecules and the costimulatory molecules, CD80 and
CD86.
Interestingly, it has been suggested that in human pDCs,
TLR9 displays a unique feature that is not shared by the
other described TLRs. Depending on the stimulus, activa-
tion of TLR9 on human pDCs can have a diVerent outcome.
The dual function of TLR9 is attributed to the distinct intra-
cellular locations where TLR9 can be triggered. Upon
encountering nucleic acids, TLR9 will traYc from the
endoplasmatic reticulum through the Golgi to the early
endosomes [47, 48]. There, TLR9 triggering may induce
the recruitment and phosphorylation of IRF7, which in turn
induces IFN secretion, thus activating an innate immune
response. In contrast, in the late endosomes, TLR9 trigger-
ing preferentially activates NF-B, which results in pheno-
typical maturation of DCs and secretion of IL-6 and TNF,
hence activating an adaptive immune response [49].
Especially IFN is produced after TLR7 or TLR9 trig-
gering [34–37, 50]. IL-12, a cytokine commonly produced
by mDCs and moDCs after TLR stimulation, is not secreted
by pDCs as found in the majority of the studies. Only Jar-
rossay et al. [35] mentioned a weak IL-12 response by
pDCs, which was possibly due to a polluting mDC subset
in the samples tested.
Some reports showed a minimal expression of TLR1 on
pDCs [36, 37, 51]. However, the possible function of TLR1
on pDCs remains ambiguous, especially since its heterodi-
meric partner TLR2 is not expressed by pDCs and pDCs do
not respond to TLR1/TLR2 ligands [35–38].
Interestingly, pDCs do not express TLR3 and TLR8.
Since both TLR3 and TLR8 bind viral ligands and pDCs
are specialized in the recognition of viral pathogens, it
would not be unlikely for pDCs to express these receptors.
Possibly, TLR8 lost its function during evolution as TLR7
binds the same ligands and shares the same signaling path-
way, leading to similar eVects. However, why pDCs lack
TLR3 expression is still unknown.
Surprisingly, pDCs also express TLR10, both at the
mRNA and protein level [37, 51, 52], but the function and
binding partner of TLR10 are yet to be identiWed. Overall,
human pDCs only express TLR7, 9 and 10 and react on
TLR7 and TLR9 activation by secreting type I IFNs, espe-
cially IFN.
Practical limitations
When comparing data obtained by diVerent groups, we
noticed inconsistencies between studies, which may be
caused by technical limitations. For instance, several
diVerent techniques to isolate fresh mDCs and pDCs from
blood were used by diVerent groups, including cell sorting
by FACS and magnetic beads. Even small impurities in
the isolated cell population can interfere with the results,
as was demonstrated by the IL-12 secretion by a small
contaminating mDC subpopulation, which was Wrst con-
tributed to the pDC population [34, 37, 50]. In addition,
most expression proWling of TLRs on DCs is performed
by RT-PCR, because of a lack of antibodies directed
against TLR molecules. But when antibodies were used,
several of them proved to be unreliable as demonstrated
by Matsumoto et al. [38] who showed that a TLR3-spe-
ciWc antibody also bound to a centrosomal protein that
shared an epitope with TLR3 and incorrectly suggested
TLR3 protein expression in pDCs, although TLR3 mRNA
expression was absent.
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Even small impurities in the isolated cells (»1–5%) can
cause problems. Furthermore, interpretation of mRNA
expression level is highly subjective and does not always
correlate with the expression level of the encoded protein.
In addition, mRNA levels do not reveal the localization of
the protein. Perhaps TLR proteins residing in intracellular
compartments and showing high mRNA expression are
only eVective when transported to another compartment
or to the extracellular membrane after stimulation. For
instance, it has been demonstrated that the ectodomain of
TLR9 is cleaved in the endolysosome before TLR9 is
transported to endosomal compartments and that only the
cleaved form of TLR9 is functional after ligand binding
[53]. In addition, post-translational modiWcation, such as
ubiquitination, may aVect TLR expression and functional-
ity [54]. Therefore, next to TLR expression proWling, func-
tional studies using TLR ligands are important in
establishing whether the TLR expressed in a given DC
subtype is functional. However, cytokine responses and
DC maturation may also be caused by non-TLR receptors,
such as C-type lectins or undiscovered TLRs that recog-
nize the same pathogenic ligands. In addition, it is very
important to use highly puriWed TLR ligands, since minor
contaminations of, for instance, endotoxin may obscure
the results.
Implications for immunotherapy of cancer
The above summarized data suggest that mDCs mainly
recognize and respond to bacterial and fungal antigens,
whereas pDCs are specialized for viral recognition. How-
ever, although pDC and mDC subsets have diVerent
functional specialization, as they express a diVerent rep-
ertoire of TLRs and respond dissimilarly to microbial
stimuli, both pDCs and mDCs may be of importance for
the induction of anti-tumor responses in DC vaccination
therapy. MDCs as well as pDCs can induce Th1
responses after TLR stimulation [34] and anti-tumor
responses induced by pDCs have been reported in animal
models [55, 56].
Reactivation of tumor-inWltrating DCs
Several studies suggest that human pDCs have the abil-
ity to inWltrate solid tumors since they are found in a
wide variety of human cancers, including breast cancer
[57], head and neck cancer [58] and ovarian cancer [59].
Soluble factors secreted by the tumor create a suppres-
sive environment, thus preventing diVerentiation and
maturation of inWltrating DCs [60–62]. Despite their
ability to inWltrate solid tumors, pDCs on the site are
unable to sense DNA via TLRs and become activated.
These Wndings have been correlated with poor prognosis
[57] and are linked to the induction of regulatory T cells
[63]. Although pDCs at the tumor site have a pre-pDC
phenotype and maintain the immunosuppressive envi-
ronment, several studies have now demonstrated that
topical TLR7-agonist (Imiquimod) treatment led to
enhanced pDC recruitment and type I IFN production by
resident pDCs at the tumor site, which in turn generated
an inXammatory environment resulting in tumor regres-
sion [64, 65]. Furthermore, activation of resident tumor
pDCs can also be achieved by intratumoral injection of
CpG motifs inducing TLR9 triggering. This strategy has
therapeutic potential in patients with basal cell carci-
noma and melanoma skin metastases [66]. Since TLR9
is believed to be expressed only on pDCs, CpG injection
will not directly activate mDCs. Therefore, intratumoral
injection of other TLR ligands, such as the TLR7/8
ligand R848 that activates both mDCs and pDCs, will be
even more potent in reactivating DCs at the tumor site
and might favor the induction of anti-tumor immune
responses.
DC vaccination with pDCs and mDCs
Recent studies suggest that pDCs and mDCs cooperate and
act synergistically (Fig. 1). In mice, pDCs not only directly
induce tumor antigen-speciWc CD8+ T cell immune
responses, but also enhance the ability of mDCs to present
tumor antigens to T cells [67]. Moreover, human mDCs and
pDCs activate each other after speciWc stimulation of only
one of the DC subsets with appropriate TLR ligands in vitro
[68]. These studies suggest that also in a clinical setting,
such as DC vaccination in cancer patients, vaccination with
both pDCs and mDCs may generate stronger anti-tumor
responses than vaccination with moDCs alone.
We recently completed a clinical trial with tumor
antigen-loaded, TLR ligand-matured pDCs in stage IV mel-
anoma patients, which appeared feasible and safe
(manuscript in preparation). In the majority of patients vac-
cinated with pDCs, we found responses against the moni-
toring protein, demonstrating that even small numbers
of naturally occurring DCs can induce immunological
responses. When mDCs and pDCs would be used in combi-
nation, both DC subsets will need stimulation with care-
fully selected TLR ligands, due the fact that they express a
diVerent repertoire of TLRs (Table 1; Fig. 1). Since TLRs
act in synergy [69], the combination of diVerent TLR
ligands may even be more potent (Fig. 1). It is of impor-
tance to Wnd TLR ligands that either induce optimal matu-
ration of both mDCs and pDCs, or at least do not interfere
with maturation of either DC subtype. Future studies will
address whether mDC-pDC cross talk can improve anti-
tumor responses in cancer patients.
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Concluding remarks
To date, most clinical studies apply moDCs for DC vacci-
nation of cancer patients. As described above, culturing
procedures required to obtain moDCs may aVect their abil-
ity to induce anti-tumor immunity. We hypothesize that
TLR-matured blood DCs may be a potent alternative, since
these cells do not require extensive culturing and can be
isolated in a closed system in accordance to GMP stan-
dards. Despite their low frequencies, human naturally
occurring DCs may have superior migratory and antigen-
presenting capacities compared to in vitro-generated
moDCs, especially when combining diVerent DC subsets.
Alternatively, the potency of in vitro-generated moDCs
could be improved by electroporation with mRNA-encod-
ing proteins involved in DC maturation, migration and T
cell activation, as was suggested by Bonehill et al. [70].
Future studies will need to prove the feasibility and potency
of TLR-matured DC subsets for DC-based immunotherapy.
Acknowledgments This work was supported by grants from the
Dutch Cancer Society (KWF 2003-2917, KWF 2004-3126, KWF
2004-3127, KWF 2006-3699), the Netherlands Organization for Sci-
entiWc Research (NWO ZonMW, Vidi grant 917.76.363, Vici grant
918.66.615), the TIL-foundation, the NOTK-foundation and the EU
(Cancerimmunotherapy, LSHC-CT-2006-518234 and DC-Thera, LSHB-
CT-2004-512074).
References
1. Lesterhuis WJ, de Vries IJM, Adema GJ, Punt CJA (2004) Den-
dritic cell-based vaccines in cancer immunotherapy: an update on
clinical and immunological results. Ann Oncol 15:145–151
2. Lesterhuis WJ, Aarntzen EHJG, Vries IJM, Schuurhuis DH,
Figdor CG, Adema GJ, Punt CJA (2008) Dendritic cell vaccines in
melanoma: from promise to proof? Crit Rev Oncol Hematol
66:118–134
3. Breckpot K, Corthals J, Bonehill A, Michiels A, Tuyaerts S, Aerts
C, Heirman C, Thielemans K (2005) Dendritic cells diVerentiated
in the presence of IFN-beta and IL-3 are potent inducers of an anti-
gen-speciWc CD8(+) T cell response. J Leukocyte Biol 78:898–
908
4. Soruri A, Kiafard Z, Dettmer C, Riggert J, Kohl J, Zwirner J
(2003) IL-4 down-regulates anaphylatoxin receptors in monocytes
and dendritic cells and impairs anaphylatoxin-induced migration
in vivo. J Immunol 170:3306–3314
5. de Vries IJM, Lesterhuis WJ, Scharenborg NM, Engelen LPH,
Ruiter DJ, Gerritsen MJP, Croockewit S, Britten CM, Torensma
R, Adema GJ, Figdor CG, Punt CJA (2003) Maturation of
dendritic cells is a prerequisite for inducing immune responses in
advanced melanoma patients. Clin Cancer Res 9:5091–5100
6. Netea MG, Van der Meer JWM, Sutmuller RP, Adema GJ,
Kullberg BJ (2005) From the Th1/Th2 paradigm towards a
Fig. 1 TLR activation of human DC subsets can enhance anti-tumor
responses in vivo. DC subsets express a wide repertoire of TLRs,
which upon triggering induce the activation of the DC. Where pDCs
predominantly express TLRs in endosomal compartments, mDCs have
a broader TLR expression pattern, both at the endosomal and extracel-
lular membranes. By cross talk between mDCs and pDCs, either by
cell–cell contact or soluble factors such as type I IFNs, TLR-induced
activation of one subset can lead to the activation of the other subset.
Type I IFNs appear to yield more potent mDCs in terms of IL-12 secre-
tion, induction of tumor-speciWc cytotoxic T cells and Th1 responses
in vitro. On direct TLR activation, mDCs gain the ability to secrete
large quantities of IL-12, which is beneWcial for the polarization of a
Th1 response. Both mDCs and pDCs have the capacity to evoke T
helper cell responses. Moreover, pDCs can promote the ability of
mDCs to cross-prime CD8+ T cells. Consequently, TLR activation of
mDCs and pDCs and the cross talk between those two subsets can
strongly enhance anti-tumor responses in vivo
Cancer Immunol Immunother (2010) 59:1573–1582 1581
123
toll-like receptor/T-helper bias. Antimicrob Agents Chemother
49:3991–3996
7. Banchereau J, Steinman RM (1998) Dendritic cells and the control
of immunity. Nature 392:245–252
8. Shortman K, Liu YJ (2002) Mouse and human dendritic cell sub-
types. Nat Rev Immunol 2:151–161
9. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S,
Buck DW, Schmitz J (2000) BDCA-2, BDCA-3 and BDCA-4:
three markers for distinct subsets of dendritic cells in human
peripheral blood. J Immunol 165:6037–6046
10. Colonna M, Trinchieri G, Liu YJ (2004) Plasmacytoid dendritic
cells in immunity. Nat Immunol 5:1219–1226
11. Corcoran L, Ferrero I, Vremec D, Lucas K, Waithman J, O’KeeVe
M, Wu L, Wilson A, Shortman K (2003) The lymphoid past of
mouse plasmacytoid cells and thymic dendritic cells. J Immunol
170:4926–4932
12. D’Amico A, Wu L (2003) The early progenitors of mouse den-
dritic cells and plasmacytoid predendritic cells are within the bone
marrow hemopoietic precursors expressing Flt3. J Exp Med
198:293–303
13. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG (2003)
Flt3 ligand regulates dendritic cell development from Flt3(+) lym-
phoid and myeloid-committed progenitors to Flt3(+) dendritic
cells in vivo. J Exp Med 198:305–313
14. Hochrein H, Schlatter B, O’KeeVe M, Wagner C, Schmitz F,
Schiemann M, Bauer S, Suter M, Wagner H (2004) Herpes sim-
plex virus type-1 induces IFN-alpha production via Toll-like
receptor 9-dependent and -independent pathways. Proc Natl Acad
Sci U S A 101:11416–11421
15. Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber
EP (1998) A novel dendritic cell population in human blood: one-
step immunomagnetic isolation by a speciWc mAb (M-DC8) and in
vitro priming of cytotoxic T lymphocytes. Eur J Immunol
28:4084–4093
16. MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schmitz J,
Hart DNJ (2002) Characterization of human blood dendritic cell
subsets. Blood 100:4512–4520
17. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C,
Bardelli M, Montagna D, Locatelli F, Wack A (2007) Functional
specialization of human circulating CD16 and CD1c myeloid den-
dritic-cell subsets. Blood 109:5371–5379
18. Lindstedt M, Lundberg K, Borrebaeck CAK (2005) Gene family
clustering identiWes functionally associated subsets of human in
vivo blood and tonsillar dendritic cells. J Immunol 175:4839–4846
19. Huysamen C, Willment JA, Dennehy KM, Brown GD (2008)
CLEC9A is a novel activation C-type lectin-like receptor
expressed on BDCA3(+) dendritic cells and a subset of mono-
cytes. J Biol Chem 283:16693–16701
20. Sallusto F, Lanzavecchia A (1994) EYcient presentation of solu-
ble-antigen by cultured human dendritic cells is maintained by
granulocyte-macrophage colony-stimulating factor plus interleu-
kin-4 and down-regulated by tumor-necrosis-factor-alpha. J Exp
Med 179:1109–1118
21. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM (2004) Den-
dritic cell immunotherapy: mapping the way. Nat Med 10:475–
480
22. Wilson NS, El Sukkari D, Belz GT, Smith CM, Steptoe RJ, Heath
WR, Shortman K, Villadangos JA (2003) Most lymphoid organ
dendritic cell types are phenotypically and functionally immature.
Blood 102:2187–2194
23. JeVord M, Schnurr M, Toy T, Masterman KA, Shin A, Beecroft T,
Tai TY, Shortman K, Shackleton M, Davis ID, Parente P, Luft T,
Chen WS, Cebon J, Maraskovsky E (2003) Functional comparison
of DCs generated in vivo with Flt3 ligand or in vitro from blood
monocytes: diVerential regulation of function by speciWc classes
of physiologic stimuli. Blood 102:1753–1763
24. Osugi Y, Vuckovic S, Hart DNJ (2002) Myeloid blood CD11c(+)
dendritic cells and monocyte-derived dendritic cells diVer in their
ability to stimulate T lymphocytes. Blood 100:2858–2866
25. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet
N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N,
Pineiro L, Steinman R, Fay J (2001) Immune and clinical respons-
es in patients with metastatic melanoma to CD34(+) progenitor-
derived dendritic cell vaccine. Cancer Res 61:6451–6458
26. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and
innate immunity. Cell 124:783–801
27. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the
adaptive immune responses. Nat Immunol 5:987–995
28. Yarovinsky F, Zhang DK, Andersen JF, Bannenberg GL, Serhan
CN, Hayden MS, Hieny S, Sutterwala FS, Flavell RA, Ghosh S,
Sher A (2005) TLR11 activation of dendritic cells by a protozoan
proWlin-like protein. Science 308:1626–1629
29. Zhang DK, Zhang GL, Hayden MS, Greenblatt MB, Bussey C,
Flavell RA, Ghosh S (2004) A toll-like receptor that prevents
infection by uropathogenic bacteria. Science 303:1522–1526
30. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Steven-
son MA, Calderwood SK (2002) Novel signal transduction path-
way utilized by extracellular HSP70––role of Toll-like receptor
(TLR) 2 AND TLR4. J Biol Chem 277:15028–15034
31. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-
Nejad P, Kirschning CJ, da Costa C, Rammensee HG, Wagner H,
Schild H (2002) The endoplasmic reticulum-resident heat shock
protein Gp96 activates dendritic cells via the toll-like receptor 2/4
pathway. J Biol Chem 277:20847–20853
32. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev
Immunol 4:499–511
33. Hovanessian AG (2007) On the discovery of interferon-inducible,
double-stranded RNA activated enzymes: the 2–5oligoadenylate
synthetases and the protein kinase PKR. Cytokine Growth Factor
Rev 18:351–361
34. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K,
Ozaki Y, Tomizawa H, Akira S, Fukuhara S (2002) Interferon-
alpha and interleukin-12 are induced diVerentially by toll-like
receptor 7 ligands in human blood dendritic cell subsets. J Exp
Med 195:1507–1512
35. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia
A (2001) Specialization and complementarity in microbial mole-
cule recognition by human myeloid and plasmacytoid dendritic
cells. Eur J Immunol 31:3388–3393
36. Kadowaki N, Ho S, Antonenko S, Malefyt RD, Kastelein RA,
Bazan F, Liu YJ (2001) Subsets of human dendritic cell precursors
express diVerent toll-like receptors and respond to diVerent micro-
bial antigens. J Exp Med 194:863–869
37. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V,
Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G
(2001) Toll-like receptor expression reveals CpG DNA as a unique
microbial stimulus for plasmacytoid dendritic cells which syner-
gizes with CD40 ligand to induce high amounts of IL-12. Eur J
Immunol 31:3026–3037
38. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto
Y, Yamamoto A, Seya T (2003) Subcellular localization of toll-
like receptor 3 in human dendritic cells. J Immunol 171:3154–
3162
39. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD (2003)
The toll-like receptor 5 stimulus bacterial Xagellin induces matu-
ration and chemokine production in human dendritic cells.
J Immunol 170:5165–5175
40. Muzio M, Bosisio D, Polentarutti N, D’amico G, Stoppacciaro A,
Mancinelli R, van’t Veer C, Penton-Rol G, Ruco LP, Allavena P,
Mantovani A (2000) DiVerential expression and regulation of toll-
like receptors (TLR) in human leukocytes: selective expression of
TLR3 in dendritic cells. J Immunol 164:5998–6004
1582 Cancer Immunol Immunother (2010) 59:1573–1582
123
41. Renn CN, Sanchez DJ, Ochoa MT, Legaspi AJ, Oh CK, Liu PT,
Krutzik SR, Sieling PA, Cheng GH, Modlin RL (2006) TLR acti-
vation of Langerhans cell-like dendritic cells triggers an antiviral
immune response. J Immunol 177:298–305
42. Hochrein H, O’KeeVe M (2008) Dendritic cell subsets and Toll-
like receptors. In: Bauer S, Hartmann G (eds) Toll-like receptors
(TLRs) and innate immunity. Handb Exp Pharmacol, vol 183.
Springer, Berlin, pp 153–179
43. Bell MP, Svingen PA, Rahman MK, Xiong Y, Faubion WA
(2007) FOXP3 regulates TLR10 expression in human T regulatory
cells. J Immunol 179:1893–1900
44. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal
DM (2001) Regulation of Toll-like receptors in human monocytes
and dendritic cells. J Immunol 166:249–255
45. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E,
Golenbock DT, Coyle AJ, Liao SM, Maniatis T (2003) IKK epsi-
lon and TBK1 are essential components of the IRF3 signaling
pathway. Nat Immunol 4:491–496
46. Gilliet M, Cao W, Liu YJ (2008) Plasmacytoid dendritic cells:
sensing nucleic acids in viral infection and autoimmune diseases.
Nat Rev Immunol 8:594–606
47. Chockalingam A, Brooks JC, Cameron JL, Blum LK, Leifer CA
(2009) TLR9 traYcs through the Golgi complex to localize to
endolysosomes and respond to CpG DNA. Immunol Cell Biol
87:209–217
48. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG,
Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT (2004)
TLR9 signals after translocating from the ER to CpG DNA in the
lysosome. Nat Immunol 5:190–198
49. Guiducci C, Ott G, Chan JH, Damon E, Calacsan C, Matray T, Lee
KD, Man RLC, Barrat FJ (2006) Properties regulating the nature
of the plasmacytoid dendritic cell response to Toll-like receptor 9
activation. J Exp Med 203:1999–2008
50. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B,
Giese T, Endres S, Hartmann G (2002) Quantitative expression of
Toll-like receptor 1–10 mRNA in cellular subsets of human
peripheral blood mononuclear cells and sensitivity to CpG oligo-
deoxynucleotides. J Immunol 168:4531–4537
51. Flacher V, Bouschbacher M, Verronese E, Massacrier C, Sisirak
V, Berthier-Vergnes O, Saint-Vis B, Caux C, Dezutter-Dambuy-
ant C, Lebecque S, Valladeau J (2006) Human Langerhans cells
express a speciWc TLR proWle and diVerentially respond to viruses
and Gram-positive bacteria. J Immunol 177:7959–7967
52. Hasan U, ChaVois C, Gaillard C, Saulnier V, Merck E, Tancredi S,
Guiet C, Briere F, Vlach J, Lebecque S, Trinchieri G, Bates EEM
(2005) Human TLR10 is a functional receptor, expressed by B
cells and plasmacytoid dendritic cells, which activates gene tran-
scription through MyD88. J Immunol 174:2942–2950
53. Ewald SE, Lee BL, Lau L, WickliVe KE, Shi GP, Chapman HA,
Barton GM (2008) The ectodomain of Toll-like receptor 9 is
cleaved to generate a functional receptor. Nature 456:658–662
54. Chuang TH, Ulevitch RJ (2004) Triad3A, an E3 ubiquitin-protein
ligase regulating Toll-like receptors. Nat Immunol 5:495–502
55. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G,
Liu YJ, O’Garra A (2003) Flexibility of mouse classical and plas-
macytoid-derived dendritic cells in directing T helper type 1 and 2
cell development: dependency on antigen dose and diVerential
toll-like receptor ligation. J Exp Med 197:101–109
56. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith
CL, Shepherd D, Colonna M, Cerundolo V (2003) Plasmacytoid
dendritic cells prime IFN-gamma-secreting melanoma-speciWc
CD8 lymphocytes and are found in primary melanoma lesions. Eur
J Immunol 33:1052–1062
57. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I,
Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ,
Barthelemy-Dubois C, Lebecque S (2004) Dendritic cell inWltra-
tion and prognosis of early stage breast cancer. Clin Cancer Res
10:7466–7474
58. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch
D, Mack B, Giese T, Gires O, Endres S, Hartmann G (2003) Iden-
tiWcation and functional analysis of tumor-inWltrating plasmacy-
toid dendritic cells in head and neck cancer. Cancer Res 63:6478–
6487
59. Zou WP, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F,
Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustil-
nik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ
(2001) Stromal-derived factor-1 in human tumors recruits and
alters the function of plasmacytoid precursor dendritic cells. Nat
Med 7:1339–1346
60. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP
(1997) Decreased antigen presentation by dendritic cells in
patients with breast cancer. Clin Cancer Res 3:483–490
61. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S,
Valladeau J, Davoust J, Palucka KA, Banchereau J (1999) In
breast carcinoma tissue, immature dendritic cells reside within the
tumor, whereas mature dendritic cells are located in peritumoral
areas. J Exp Med 190:1417–1425
62. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC,
Caux C, Blay JY (1998) Inhibition of the diVerentiation of den-
dritic cells from CD34(+) progenitors by tumor cells: role of inter-
leukin-6 and macrophage colony-stimulating factor. Blood
92:4778–4791
63. Wei S, Kryczek I, Zou LH, Daniel B, Cheng P, Mottram P, Curiel
T, Lange A, Zou WP (2005) Plasmacytoid dendritic cells induce
CD8(+) regulatory T cells in human ovarian carcinoma. Cancer
Res 65:5020–5026
64. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G
(2003) Imiquimod in basal cell carcinoma: how does it work? Br J
Dermatol 149:57–58
65. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA (1999)
Imiquimod applied topically: a novel immune response modiWer
and new class of drug. Int J Immunopharmacol 21:1–14
66. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U
(2008) Phase 1 evaluation of intralesionally injected TLR9-agonist
PF-3512676 in patients with basal cell carcinoma or metastatic
melanoma. J Immunother 31:520–527
67. Lou YY, Liu CW, Kim GJ, Liu YJ, Hwu P, Wang G (2007) Plas-
macytoid dendritic cells synergize with myeloid dendritic cells in
the induction of antigen-speciWc antitumor immune responses.
J Immunol 178:1534–1541
68. Piccioli D, Sammicheli C, Tavarini S, Nuti S, Frigimelica E,
Manetti AGO, Nuccitelli A, Aprea S, Valentini S, Borgogni E,
Wack A, Valiante NM (2009) Human plasmacytoid dendritic cells
are unresponsive to bacterial stimulation and require a novel type
of cooperation with myeloid dendritic cells for maturation. Blood
113:4232–4239
69. Trinchieri G, Sher A (2007) Cooperation of Toll-like receptor sig-
nals in innate immune defence. Nat Rev Immunol 7:179–190
70. Bonehill A, Tuyaerts S, Van NuVel AM, Heirman C, Bos TJ,
Fostier K, Neyns B, Thielemans K (2008) Enhancing the T-cell
stimulatory capacity of human dendritic cells by co-electropora-
tion with CD40L, CD70 and constitutively active TLR4 encoding
mRNA. Mol Ther 16:1170–1180
71. Kokkinopoulos I, Jordan WJ, Ritter MA (2005) Toll-like receptor
mRNA expression patterns in human dendritic cells and mono-
cytes. Mol Immunol 42:957–968
